Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEQH6J)

• Drug Name: Flavone Drug Info
• Synonyms: Flavone; FLAVONE; 525-82-6; 2-Phenylchromone; 2-Phenyl-4H-chromen-4-one; 2-Phenyl-4-chromone; Asmacoril; 2-Phenyl-4H-1-benzopyran-4-one; 2-Phenyl-4-benzopyron; 4H-1-Benzopyran-4-one, 2-phenyl-; Chromocor; Cromaril; 2-phenylchromen-4-one; Phenylchromone; 2-Phenyl-chromen-4-one; 2-Phenyl-gamma-benzopyrone; 2-Phenylbenzopyran-4-one; Cromarile; 2-Phenyl-4H-benzopyran-4-one; Flavon; 2-Phenylchrome; UNII-S2V45N7G3B; NSC 19028; 2-Phenyl-4H-chromen-4-on; CCRIS 4288; NSC19028; EINECS 208-383-8; NSC-19028; BRN 0157598

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1] , [2]

• Cross-matching ID:
  PubChem CID: 10680
  ChEBI ID: CHEBI:42491
  CAS Number: CAS 525-82-6
  TTD Drug ID: DMEQH6J
  INTEDE Drug ID: DR2144

Molecule-Related Drug Atlas

Drug(s) Metabolized By Cytochrome P450 2A6 (CYP2A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Solid tumour/cancer	2A00-2F9Z	Approved	[10]
Progesterone	DMUY35B	Premature labour	JB00	Approved	[11]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[12]
Acetaminophen	DMUIE76	Pain	MG30-MG3Z	Approved	[13]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[11]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Metronidazole	DMTIVEN	Amoebiasis	1A36	Approved	[15]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[16]
Nicotine	DMWX5CO	Nicotine dependence	6C4A.2	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[11]

Drug(s) Metabolized By Biphenyl dioxygenase (bphC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isoflavone	DM7U58J	Asthma	CA23	Phase 4	[9]
AUS-131	DMUXO3Z	Benign prostatic hyperplasia	GA90	Phase 2	[9]
Flavanone	DMNWIYM	Discovery agent	N.A.	Investigative	[9]

Drug(s) Metabolized By Naphthalene dioxygenase (doxB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isoflavone	DM7U58J	Asthma	CA23	Phase 4	[9]

Drug(s) Targeting Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[18]
Letrozole	DMH07Y3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[19]
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[19]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[20]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[21]
Testolactone	DMVY4GN	Breast cancer	2C60-2C65	Approved	[22]
Atamestane + Toremifene	DM3QLK2	Breast cancer	2C60-2C65	Phase 3	[23]
LIAROZOLE	DM4OYXE	Dermatological disease	DA24.Y	Phase 2/3	[6]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[24]
Dextromethorphan+quinidine	DMFI5J4	Diabetic neuropathy	8C0Z	Phase 2	[25]

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[26]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[27]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[28]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[29]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[30]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[31]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[32]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[29]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[29]
Methylthioadenosine	DMC8J6F	Multiple sclerosis	8A40	Terminated	[33]

Drug(s) Targeting Androgen receptor messenger RNA (AR mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[34]
BAY 86-5044	DMRZLU4	Breast cancer	2C60-2C65	Phase 2	[35]
TRC-253	DMXI8CD	Prostate cancer	2C82.0	Phase 1/2	[36]
ISIS-AR	DM8P3N5	Prostate cancer	2C82.0	Phase 1	[37]
EZN-4176	DMNPS59	Prostate cancer	2C82.0	Phase 1	[38]
Eugenol	DM7US1H	Discovery agent	N.A.	Patented	[39]
RU-58841	DMMEAZ2	Acne vulgaris	ED80	Discontinued in Phase 1	[40]
Apigenin	DMI3491	Discovery agent	N.A.	Investigative	[5]
Kaempferol	DMHEMUB	Discovery agent	N.A.	Investigative	[5]
LGD-5552	DM67KWM	Discovery agent	N.A.	Investigative	[41]

Drug(s) Targeting GABA(A) receptor alpha-1 (GABRA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[42]
Zolpidem	DMWOSKJ	Insomnia	7A00-7A0Z	Approved	[43]
Methoxyflurane	DML0RAE	Anaesthesia	9A78.6	Approved	[42]
Nitrazepam	DMEGIQ6	Epilepsy	8A60-8A68	Approved	[42]
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	Approved	[44]
Clobazam - Lundbeck	DMW1OQ0	Anxiety disorder	6B00-6B0Z	Approved	[42]
Hexobarbital	DMQ314B	Anaesthesia	9A78.6	Approved	[42]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[45]
Meprobamate	DMHM93Y	Anxiety disorder	6B00-6B0Z	Approved	[42]
Zaleplon	DMGFWSM	Insomnia	7A00-7A0Z	Approved	[46]

Drug(s) Targeting Gamma-aminobutyric acid receptor (GAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenobarbital	DMXZOCG	Seizure disorder	8A6Z	Approved	[42]
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	Approved	[47]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[45]
Clonazepam	DMTO13J	Epilepsy	8A60-8A68	Approved	[48]
Piperazine	DMTY9LU	Ascariasis	1F62	Approved	[49]
Alpidem	DMN7Y9K	Anxiety disorder	6B00-6B0Z	Approved	[50]
Moxidectin	DMYGHX5	Onchocerciasis	1F6A	Approved	[51]
DP-VPA	DMGOXPQ	Bipolar disorder	6A60	Approved	[52]
Androsterone	DMITJAK	N. A.	N. A.	Phase 3	[47]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[53]

Drug(s) Targeting Adenosine A2b receptor (ADORA2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[46]
Vidarabine	DM0N85H	Herpes simplex virus infection	1F00	Approved	[46]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[27]
YT-146	DM3YVKQ	Hypertension	BA00-BA04	Phase 2	[54]
AB928	DMDOXMN	Metastatic colorectal cancer	2B91	Phase 1/2	[36]
KF-17837	DMQ6DLZ	Parkinson disease	8A00.0	Phase 1	[55]
Xanthine	DMFBOQ7	Apnea	MD11.0	Phase 1	[56]
CVT-6883	DMY84TW	Asthma	CA23	Phase 1	[57]
PBF-1129	DMOPGXM	Non-small-cell lung cancer	2C25.Y	Phase 1	[36]
PF-1913539	DMXEU14	Alzheimer disease	8A20	Discontinued in Phase 3	[58]

Drug(s) Targeting Adenosine A1 receptor (ADORA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Orthostatic hypotension	BA21	Approved	[59]
Rolofylline	DMSZPR3	Heart failure	BD10-BD13	Phase 3	[60]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[27]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[61]
SELODENOSON	DMQM3IX	Cardiac arrhythmias	BC9Z	Phase 2	[62]
Apaxifylline	DMQMV9F	Cognitive impairment	6D71	Phase 2	[63]
SLV320	DM867BJ	Heart failure	BD10-BD13	Phase 2	[64]
DTI-0009	DMV84OK	Atrial fibrillation	BC81.3	Phase 2	[62]
Capadenoson	DMYWO62	Atrial fibrillation	BC81.3	Phase 2	[65]
BAY 1067197	DM4JGNH	Heart failure	BD10-BD13	Phase 2	[66]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A1 receptor (ADORA1)	TTK25J1	AA1R_HUMAN	Antagonist	[3]
Adenosine A2b receptor (ADORA2B)	TTNE7KG	AA2BR_HUMAN	Antagonist	[3]
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Antagonist	[3] , [4]
Androgen receptor messenger RNA (AR mRNA)	TTKPW01	ANDR_HUMAN	Inhibitor	[5]
Aromatase (CYP19A1)	TTSZLWK	CP19A_HUMAN	Inhibitor	[6]
GABA(A) receptor alpha-1 (GABRA1)	TT1MPAY	GBRA1_HUMAN	Inhibitor	[7]
Gamma-aminobutyric acid receptor (GAR)	TTNJYV2	NOUNIPROTAC	Inhibitor	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[8]
Naphthalene dioxygenase (doxB)	DEE76YZ	NDOB_PSEU8	Substrate	[9]
Biphenyl dioxygenase (bphC)	DEUX61H	BPHC_PSEFK	Substrate	[9]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 409).
• [2] Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201.
• [3] Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301.
• [4] Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996 Feb 2;39(3):781-8.
• [5] Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
• [6] Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
• [7] Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997).
• [8] Site-specific oxidation of flavanone and flavone by cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 2019 Jul;49(7):791-802.
• [9] Flavonoids biotransformation by bacterial non-heme dioxygenases, biphenyl and naphthalene dioxygenase. Appl Microbiol Biotechnol. 2011 Jul;91(2):219-28.
• [10] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [11] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [12] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [13] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [14] Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
• [15] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [16] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [17] CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
• [18] Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
• [19] Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
• [20] Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
• [21] Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
• [22] Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
• [23] Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7.
• [24] Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
• [25] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [26] A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
• [27] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [28] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [29] 2011 Pipeline of Can-Fite BioPharm.
• [30] Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
• [31] 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
• [32] Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
• [33] Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55.
• [34] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
• [35] Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
• [36] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [37] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
• [38] 2011 Pipeline of Santaris Pharma.
• [39] Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2111-4.
• [40] Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4.
• [41] Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9.
• [42] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [43] Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
• [44] Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
• [45] 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
• [46] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [47] Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
• [48] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [49] Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31.
• [50] Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18.
• [51] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [52] DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3.
• [53] Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
• [54] Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
• [55] Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
• [56] Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6.
• [57] GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.
• [58] Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem Pharmacol. 1999 Jan 1;57(1):65-75.
• [59] Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
• [60] Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
• [61] Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
• [62] Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
• [63] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
• [64] Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
• [65] A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
• [66] Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.